• Join our community!

    Do you have questions about celiac disease or the gluten-free diet?

  • Ads by Google:
     




    Get email alerts Subscribe to Celiac.com's FREE weekly eNewsletter

    Ads by Google:



       Get email alertsSubscribe to Celiac.com's FREE weekly eNewsletter

  • Member Statistics

    77,679
    Total Members
    3,093
    Most Online
    OliviaM19
    Newest Member
    OliviaM19
    Joined
  • 0

    Takeda Taps PvP Biologics to Develop Celiac Disease Therapy


    Jefferson Adams
    Image Caption: Photo: CC--Kathy & Sam

    Celiac.com 03/10/2017 - PvP Biologics, a business spun out of the University of Washington, now has a $35 million deal with Takeda Pharmaceutical to develop its therapy for celiac disease. PvP Biologics is developing an enzyme that can be taken orally and survive in the harsh acidic environment of the stomach. That enzyme is called KumaMax.


    Ads by Google:




    ARTICLE CONTINUES BELOW ADS
    Ads by Google:



    Under the terms of the agreement, Takeda will fund $35 million in PvP's research and development of the therapy through phase 1 clinical trials. The agreement gives Takeda Pharmaceutical the exclusive option to acquire PvP for an undisclosed fee upon successful completion.

    PvP Biologics has its roots in a University of Washington tech incubator program, but spun out on its own in 2016, in advance of its arrangement with Takeda.

    Says Adam Simpson, president and CEO of PvP Biologics, "Takeda's GI experience and capabilities are a great fit with our goal of developing a novel oral enzyme therapy to make a meaningful impact on the lives of people with celiac disease."

    The enzyme-driven KumaMax works by targeting gliadin, the parts of gluten that cause the autoimmune reaction leading to celiac disease. The company hopes to prevent the adverse immune reaction seen in celiac sufferers, by breaking down the gliadin.

    Like most similar enzyme therapies, KumaMax is not designed to be a cure for celiac disease. It is designed to help prevent adverse reactions from accidental gluten contamination.

    In a statement by the company, Asit Parikh, head of the gastroenterology therapeutic area for Takeda, says that "KumaMax could address a significant unmet need for celiac patients who are unable to completely avoid gluten exposure in their diets, and thus continue to experience debilitating symptoms."

     Read more at BizJournals.com.

    0


    User Feedback

    Recommended Comments

    Guest dappy

    Posted

    "KumaMax is not designed to be a cure for celiac disease. It is designed to help prevent adverse reactions from accidental gluten contamination."An incredible waste of time and even worse a lot of money that should be spent for curing celiac.

    Share this comment


    Link to comment
    Share on other sites
    Guest dappy

    Posted

    This is an incredible waste of time and an enormous amount of money - really for just a band aid, not a cure. Put the time and money to better use looking for an actual cure!!

    Share this comment


    Link to comment
    Share on other sites
    Guest admin

    Posted

    "KumaMax is not designed to be a cure for celiac disease. It is designed to help prevent adverse reactions from accidental gluten contamination."An incredible waste of time and even worse a lot of money that should be spent for curing celiac.

    There are many people who would like to eat out in restaurants, or who travel for a living. For those people such a product could be helpful.

    Share this comment


    Link to comment
    Share on other sites
    Guest Jeff Adams

    Posted

    This is an incredible waste of time and an enormous amount of money - really for just a band aid, not a cure. Put the time and money to better use looking for an actual cure!!

    Plenty of people would welcome such treatment options. Others might not. I don't see the world as being better off because such treatments are being developed.

    Share this comment


    Link to comment
    Share on other sites
    Guest Jeff Adams

    Posted

    "KumaMax is not designed to be a cure for celiac disease. It is designed to help prevent adverse reactions from accidental gluten contamination."An incredible waste of time and even worse a lot of money that should be spent for curing celiac.

    Currently, there are numerous efforts to develop new and effective therapies, treatments and even vaccines for celiac disease. Compare that to just ten years ago. A private company putting private money into researching enzyme therapy doesn't really hurt people with celiac disease. Some might welcome protection against moderate gluten contamination.

    Share this comment


    Link to comment
    Share on other sites


    Your content will need to be approved by a moderator

    Guest
    You are commenting as a guest. If you have an account, please sign in.
    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • Ads by Google:

  • About Me

    Jefferson Adams is a freelance writer living in San Francisco. He has covered Health News for Examiner.com, and provided health and medical content for Sharecare.com. His work has appeared in Antioch Review, Blue Mesa Review, CALIBAN, Hayden's Ferry Review, Huffington Post, the Mississippi Review, and Slate, among others.

  • Popular Contributors

  • Ads by Google:

  • Who's Online   5 Members, 0 Anonymous, 391 Guests (See full list)

  • Related Articles

    Jefferson Adams
    Celiac.com 04/18/2015 - Research is underway on a number of new drugs intended to celiac disease treatment beyond a simple gluten-free diet. However, even though several drugs are in Phase 2 trials and results appear promising, discussion around regulatory endpoints is just beginning.
    A research team recently reviewed endpoints for Phase 2 and 3 trials of new celiac disease drugs currently under development, and detailed their results in a scientific paper. The team included Klaus Gottlieb, Jill Dawson, Fez Hussain and Joseph A. Murray. They are variously affiliated with the department of Immunology and Internal Medicine of Medical Strategy & Science, Quintiles, Durham, NC, USA, with Corporate Communications, Quintiles, Durham, NC, USA, and with the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    In the paper, the team discusses celiac drugs currently under development, along with trial endpoints, such as patient-reported outcomes, histology, serology, gene expression analysis and other tests.
    They outline the differing requirements for proof-of-concept Phase 2 trials and Phase 3 registration trials, with a particular emphasis on current thinking in regulatory agencies. They conclude their paper with recommendations and a glossary of regulatory terms, to enable readers who are less familiar with regulatory language to take maximum advantage of this review.
    Stay tuned for more news and information on all developments concerning trials of new celiac drug treatments.
    Source:
    Gastroenterology Report, Oxford Journals. 10.1093/gastro/gov006

    Jefferson Adams
    Celiac.com 05/26/2015 - If recent reports are any indication, the University of Washington's PR team might be getting ahead of the facts with claims that the university research team is close to developing a cure for celiac disease.
    Numerous articles are claiming that UW researchers are working to develop an enzyme-laden pill that would break down gluten in the stomach, thus permitting people with celiac disease to eat wheat. Hence, the 'cure' idea. The enzyme, it is said, would break it apart into amino acids that could be absorbed with no risk of adverse reaction for people with celiac disease. Well, an enzyme that breaks down gluten is not necessarily the same thing as a 'cure' for celiac disease.
    Ingrid Swanson Pultz, who leads the research project describes the substance as a protein that people with celiac disease will consume orally. The team is looking to begin FDA mandated tests and human trials will sometime in the next two years. The drug "really stands to make an impact on people's lives," Pultz said.
    However, UW is not the only institution working on drugs to treat celiac disease. There are several drug treatments in progress. It's unclear at present, and will remain unclear until the human trial phase whether the enzyme will permit safe gluten consumption by people with celiac disease, or whether it would permit limited gluten consumption within certain parameters.
    In fact, given the numerous products currently under development for celiac disease treatment, and hoping to see release in the next few years, we're likely to hear many claims, much hypes, and plenty of marketing and PR flash.
    Until we actually have a product that works safely and effectively, it seems that any claims regarding a cure for celiac disease are largely overblown PR smoke. That means you, University of Washington. 
    Source:
    http://www.komonews.com/news/health/UW-Researchers-developing-cure-for-celiac-disease-302653671.html

    Jefferson Adams
    Celiac.com 11/05/2015 - Professional reports on various aspects celiac disease and gluten-free issues can be helpful for numerous people seeking to better understand what the current and future landscape will look like. 
    The latest such report is the EpiCast Report: Celiac Disease – Epidemiology Forecast to 2023. The celiac disease EpiCast Report provides an overview of the risk factors, co-morbidities, and the global and historical trends for celiac disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK).
    In that report, GlobalData epidemiologists forecast that the number of total prevalent cases of celiac disease in the 6MM is expected to grow to 8.08 million cases in 2023 at a rate of 3.92% per year during the forecast period.
    The number of diagnosed prevalent cases in the 6MM is expected to increase by 4.61% over the next decade to 1.11 million cases in 2023.
    According to the literature, GlobalDatas forecast and analysis is based on a thorough literature review and from primary research results, followed by a careful review of selected secondary research studies and validation of study findings with primary research by GlobalData epidemiologists.
    The report stands out primarily because GlobalData epidemiologists maintained a consistent case-finding definition and forecasting methodology for celiac disease throughout the 6MM, which allows for a meaningful comparison of the total and diagnosed prevalent cases of celiac disease in these markets.
    The report further breaks down total prevalent cases of celiac disease by sex, thus providing a detailed analysis of the patient population characteristic of celiac disease. Additionally, GlobalData epidemiologists also provided a realistic trend forecast for the total and diagnosed prevalence of celiac disease based on insights gained through the analysis of historical data.
    Lastly, the report also includes a comprehensive 10-year epidemiological celiac disease forecast broken down by sex and age (0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and =70 years), and a 10-year epidemiological forecast for the diagnosed prevalent cases of celiac disease in the 6MM.
    Source:
    Medgadget.com

    Jefferson Adams
    Celiac.com 09/26/2016 - Previous studies have indicated an increase in celiac disease rates in the United States, but these studies have been done on narrow populations, and did not produce results that are nationally representative.
    Researchers recently released an new comprehensive report, called, Time Trends in the Prevalence of Celiac Disease and Gluten-Free Diet in the US Population: Results From the National Health and Nutrition Examination Surveys 2009-2014. The research team included Hyun-seok Kim, MD, MPH; Kalpesh G. Patel, MD1; Evan Orosz, DO; Neil Kothari, MD; Michael F. Demyen, MD; Nikolaos Pyrsopoulos, MD, PhD, MBA; and Sushil K. Ahlawat, MD. They are variously affiliated with the Division of Gastroenterology and the Department of Medicine at Rutgers New Jersey Medical School in Newark.
    Using data from the National Health and Nutrition Examination Surveys, a team of researchers recently examined current trends in both celiac disease rates, and gluten-free diet adherence.
    Currently, far more people follow a gluten-free diet than have celiac disease. The numbers of people eating gluten-free food far outpace the levels of celiac disease diagnosis. This may be due to perceptions that the diet is healthier than a standard non-gluten-free diet.
    This research teams recent surveys examine the current trends in the prevalence of celiac disease and adherence to a gluten-free diet, including people without celiac disease, using nationally representative data from the National Health and Nutrition Examination Surveys (NHANESs) 2009-2014.
    The study evaluated 22,278 individuals over the age of 6 who completed surveys and blood tests for celiac disease. The subjects were interviewed directly regarding their prior diagnosis of celiac disease and adherence to a gluten-free diet.

    The researchers found that 106 (0.69%) individuals had a celiac disease diagnosis, and 213 (1.08%) followed a gluten-free diet but didn't have celiac disease. These results correlate to an estimated 1.76 million people with celiac disease, and 2.7 million people who follow a gluten-free diet without a diagnosis of celiac disease in the United States.

    Overall, the researchers found that the prevalence of celiac disease has remained steady (0.70% in 2009-2010, 0.77% in 2011-2012, and 0.58% in 2013-2014), however, those who follow a gluten-free diet but don't have celiac disease have increased over time (0.52% in 2009-2010, 0.99% in 2011-2012, and 1.69% in 2013-2014). The researchers conclude that the two might be related, as the decrease in gluten consumption could contribute to a plateau in those who are being diagnosed with celiac disease.
    Source:
    JAMA Intern Med. Published online September 06, 2016. doi:10.1001/jamainternmed.2016.5254

  • Recent Articles

    Jefferson Adams
    Celiac.com 06/21/2018 - Would you buy a house advertised as ‘gluten-free’? Yes, there really is such a house for sale. 
    It seems a Phoenix realtor Mike D’Elena is hoping that his trendy claim will catch the eye of a buyer hungry to avoid gluten, or, at least one with a sense of humor. D’Elena said he crafted the ads as a way to “be funny and to draw attention.” The idea, D’Elena said, is to “make it memorable.” 
    Though D’Elena’s marketing seeks to capitalizes on the gluten-free trend, he knows Celiac disease is a serious health issue for some people. “[W]e’re not here to offend anybody….this is just something we're just trying to do to draw attention and do what's best for our clients," he said. 
    Still, the signs seem to be working. D'elena had fielded six offers within a few days of listing the west Phoenix home.
    "Buying can sometimes be the most stressful thing you do in your entire life so why not have some fun with it," he said. 
    What do you think? Clever? Funny?
    Read more at Arizonafamily.com.

    Advertising Banner-Ads
    Bakery On Main started in the small bakery of a natural foods market on Main Street in Glastonbury, Connecticut. Founder Michael Smulders listened when his customers with Celiac Disease would mention the lack of good tasting, gluten-free options available to them. Upon learning this, he believed that nobody should have to suffer due to any kind of food allergy or dietary need. From then on, his mission became creating delicious and fearlessly unique gluten-free products that were clean and great tasting, while still being safe for his Celiac customers!
    Premium ingredients, bakeshop delicious recipes, and happy customers were our inspiration from the beginning— and are still the cornerstones of Bakery On Main today. We are a fiercely ethical company that believes in integrity and feels that happiness and wholesome, great tasting food should be harmonious. We strive for that in everything we bake in our dedicated gluten-free facility that is GFCO Certified and SQF Level 3 Certified. We use only natural, NON-GMO Project Verified ingredients and all of our products are certified Kosher Parve, dairy and casein free, and we have recently introduced certified Organic items as well! 
    Our passion is to bake the very best products while bringing happiness to our customers, each other, and all those we meet!
    We are available during normal business hours at: 1-888-533-8118 EST.
    To learn more about us at: visit our site.

    Jefferson Adams
    Celiac.com 06/20/2018 - Currently, the only way to manage celiac disease is to eliminate gluten from the diet. That could be set to change as clinical trials begin in Australia for a new vaccine that aims to switch off the immune response to gluten. 
    The trials are set to begin at Australia’s University of the Sunshine Coast Clinical Trials Centre. The vaccine is designed to allow people with celiac disease to consume gluten with no adverse effects. A successful vaccine could be the beginning of the end for the gluten-free diet as the only currently viable treatment for celiac disease. That could be a massive breakthrough for people with celiac disease.
    USC’s Clinical Trials Centre Director Lucas Litewka said trial participants would receive an injection of the vaccine twice a week for seven weeks. The trials will be conducted alongside gastroenterologist Dr. James Daveson, who called the vaccine “a very exciting potential new therapy that has been undergoing clinical trials for several years now.”
    Dr. Daveson said the investigational vaccine might potentially restore gluten tolerance to people with celiac disease.The trial is open to adults between the ages of 18 and 70 who have clinically diagnosed celiac disease, and have followed a strict gluten-free diet for at least 12 months. Anyone interested in participating can go to www.joinourtrials.com.
    Read more at the website for Australia’s University of the Sunshine Coast Clinical Trials Centre.

    Source:
    FoodProcessing.com.au

    Jefferson Adams
    Celiac.com 06/19/2018 - Could baking soda help reduce the inflammation and damage caused by autoimmune diseases like rheumatoid arthritis, and celiac disease? Scientists at the Medical College of Georgia at Augusta University say that a daily dose of baking soda may in fact help reduce inflammation and damage caused by autoimmune diseases like rheumatoid arthritis, and celiac disease.
    Those scientists recently gathered some of the first evidence to show that cheap, over-the-counter antacids can prompt the spleen to promote an anti-inflammatory environment that could be helpful in combating inflammatory disease.
    A type of cell called mesothelial cells line our body cavities, like the digestive tract. They have little fingers, called microvilli, that sense the environment, and warn the organs they cover that there is an invader and an immune response is needed.
    The team’s data shows that when rats or healthy people drink a solution of baking soda, the stomach makes more acid, which causes mesothelial cells on the outside of the spleen to tell the spleen to go easy on the immune response.  "It's most likely a hamburger not a bacterial infection," is basically the message, says Dr. Paul O'Connor, renal physiologist in the MCG Department of Physiology at Augusta University and the study's corresponding author.
    That message, which is transmitted with help from a chemical messenger called acetylcholine, seems to encourage the gut to shift against inflammation, say the scientists.
    In patients who drank water with baking soda for two weeks, immune cells called macrophages, shifted from primarily those that promote inflammation, called M1, to those that reduce it, called M2. "The shift from inflammatory to an anti-inflammatory profile is happening everywhere," O'Connor says. "We saw it in the kidneys, we saw it in the spleen, now we see it in the peripheral blood."
    O'Connor hopes drinking baking soda can one day produce similar results for people with autoimmune disease. "You are not really turning anything off or on, you are just pushing it toward one side by giving an anti-inflammatory stimulus," he says, in this case, away from harmful inflammation. "It's potentially a really safe way to treat inflammatory disease."
    The research was funded by the National Institutes of Health.
    Read more at: Sciencedaily.com

    Jefferson Adams
    Celiac.com 06/18/2018 - Celiac disease has been mainly associated with Caucasian populations in Northern Europe, and their descendants in other countries, but new scientific evidence is beginning to challenge that view. Still, the exact global prevalence of celiac disease remains unknown.  To get better data on that issue, a team of researchers recently conducted a comprehensive review and meta-analysis to get a reasonably accurate estimate the global prevalence of celiac disease. 
    The research team included P Singh, A Arora, TA Strand, DA Leffler, C Catassi, PH Green, CP Kelly, V Ahuja, and GK Makharia. They are variously affiliated with the Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Lady Hardinge Medical College, New Delhi, India; Innlandet Hospital Trust, Lillehammer, Norway; Centre for International Health, University of Bergen, Bergen, Norway; Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Gastroenterology Research and Development, Takeda Pharmaceuticals Inc, Cambridge, MA; Department of Pediatrics, Università Politecnica delle Marche, Ancona, Italy; Department of Medicine, Columbia University Medical Center, New York, New York; USA Celiac Disease Center, Columbia University Medical Center, New York, New York; and the Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.
    For their review, the team searched Medline, PubMed, and EMBASE for the keywords ‘celiac disease,’ ‘celiac,’ ‘tissue transglutaminase antibody,’ ‘anti-endomysium antibody,’ ‘endomysial antibody,’ and ‘prevalence’ for studies published from January 1991 through March 2016. 
    The team cross-referenced each article with the words ‘Asia,’ ‘Europe,’ ‘Africa,’ ‘South America,’ ‘North America,’ and ‘Australia.’ They defined celiac diagnosis based on European Society of Pediatric Gastroenterology, Hepatology, and Nutrition guidelines. The team used 96 articles of 3,843 articles in their final analysis.
    Overall global prevalence of celiac disease was 1.4% in 275,818 individuals, based on positive blood tests for anti-tissue transglutaminase and/or anti-endomysial antibodies. The pooled global prevalence of biopsy-confirmed celiac disease was 0.7% in 138,792 individuals. That means that numerous people with celiac disease potentially remain undiagnosed.
    Rates of celiac disease were 0.4% in South America, 0.5% in Africa and North America, 0.6% in Asia, and 0.8% in Europe and Oceania; the prevalence was 0.6% in female vs 0.4% males. Celiac disease was significantly more common in children than adults.
    This systematic review and meta-analysis showed celiac disease to be reported worldwide. Blood test data shows celiac disease rate of 1.4%, while biopsy data shows 0.7%. The prevalence of celiac disease varies with sex, age, and location. 
    This review demonstrates a need for more comprehensive population-based studies of celiac disease in numerous countries.  The 1.4% rate indicates that there are 91.2 million people worldwide with celiac disease, and 3.9 million are in the U.S.A.
    Source:
    Clin Gastroenterol Hepatol. 2018 Jun;16(6):823-836.e2. doi: 10.1016/j.cgh.2017.06.037.